Recombinant Mycobacterium smegmatis expressing an ESAT6-CFP10 fusion protein induces anti-mycobacterial immune responses and protects against Mycobacterium tuberculosis challenge in mice

Scandinavian Journal of Immunology

Volumn 72, Issue 4, 2010, Pages 349-357

  Zhang, H ^a   Peng, P ^a   Miao, S ^a   Zhao, Y ^a   Mao, F ^a   Wang, L ^a   Bai, Y ^a   Xu, Z ^a   Wei, S ^b   Shi, C ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 2; RECOMBINANT VACCINE; SODIUM CHLORIDE; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CFP-10 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; ESAT-6 PROTEIN, MYCOBACTERIUM TUBERCULOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; LUNG; LYMPHOCYTE PROLIFERATION; MOUSE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; ANIMAL; BLOOD; C57BL MOUSE; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; GENETICS; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; PROCEDURES; SPLEEN; TUBERCULOSIS; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNIZATION; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT FUSION PROTEINS; SPLEEN; TRANSFECTION; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 77956298743     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2010.02448.x     Document Type: Article

References (53)

1. Jeong YJ, Lee KS. Pulmonary tuberculosis: up-to-date imaging and management. AJR Am J Roentgenol 2008 191 : 834 844.
2. Fernando SL, Britton WJ. Genetic susceptibility to mycobacterial disease in humans. Immunol Cell Biol 2006 84 : 125 137.
3. Cardona PJ. A dynamic reinfection hypothesis of latent tuberculosis infection. Infection 2009 37 : 80 6.
4. Wiker HG, Mustafa T, Bjune GA, Harboe M. Evidence for waning of latency in a cohort study of tuberculosis. BMC Infect Dis 2010 10 : 37.
5. Park MK, Myers RA, Marzella L. Oxygen tensions and infections: modulation of microbial growth, activity of antimicrobial agents, and immunologic responses. Clin Infect Dis 1992 14 : 720 740.
6. Cardona PJ, Ruiz-Manzano J. On the nature of Mycobacterium tuberculosis-latent bacilli. Eur Respir J 2004 24 : 1044 1051.
7. Hett EC, Rubin EJ. Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev 2008 72 : 126 156.
8. Dietrich J, Lundberg CV, Andersen P. TB vaccine strategies - what is needed to solve a complex problem? Tuberculosis (Edinb) 2006 86 : 163 168.
9. Ly LH, McMurray DN. Tuberculosis: vaccines in the pipeline. Expert Rev Vaccines 2008 7 : 635 650.
10. Banerjee R, Schecter GF, Flood J, Porco TC. Extensively drug-resistant tuberculosis: new strains, new challenges. Expert Rev Anti Infect Ther 2008 6 : 713 724.
11. Abebe F, Holm-Hansen C, Wiker HG, Bjune G. Progress in serodiagnosis of Mycobacterium tuberculosis infection. Scand J Immunol 2007 66 : 176 191.
12. Bastian I, Colebunders R. Treatment and prevention of multidrug-resistant tuberculosis. Drugs 1999 58 : 633 661.
13. Breen RA, Swaden L, Ballinger J, Lipman MC. Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs 2006 66 : 2299 2308.
14. Holton SJ, Weiss MS, Tucker PA, Wilmanns M. Structure-based approaches to drug discovery against tuberculosis. Curr Protein Pept Sci 2007 8 : 365 375.
15. Rachman H, Kaufmann SH. Exploring functional genomics for the development of novel intervention strategies against tuberculosis. Int J Med Microbiol 2007 297 : 559 567.
16. Kaku T, Kawamura I, Uchiyama R, Kurenuma T, Mitsuyama M. RD1 region in mycobacterial genome is involved in the induction of necrosis in infected RAW264 cells via mitochondrial membrane damage and ATP depletion. FEMS Microbiol Lett 2007 274 : 189 195.
17. Trajkovic V, Natarajan K, Sharma P. Immunomodulatory action of mycobacterial secretory proteins. Microbes Infect 2004 6 : 513 519.
18. Renshaw PS, Panagiotidou P, Whelan A et al. Conclusive evidence that the major T-cell antigens of the Mycobacterium tuberculosis complex ESAT-6 and CFP-10 form a tight, 1:1 complex and characterization of the structural properties of ESAT-6, CFP-10, and the ESAT-6*CFP-10 complex. Implications for pathogenesis and virulence. J Biol Chem 2002 277 : 21598 21603.
19. Guinn KM, Hickey MJ, Mathur SK et al. Individual RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis. Mol Microbiol 2004 51 : 359 370.
20. Gicquel B. Towards new mycobacterial vaccines. Dev Biol Stand 1994 82 : 171 178.
21. Shi C, Wang X, Zhang H, Xu Z, Li Y, Yuan L. Immune responses and protective efficacy induced by 85B antigen and early secreted antigenic target-6 kDa antigen fusion protein secreted by recombinant bacille Calmette- Guérin. Acta Biochim Biophys Sin 2007 39 : 290 296.
22. Brandt L, Oettinger T, Holm A, Andersen AB, Andersen P. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol 1996 157 : 3527 3533.
23. + T cells recognizing CFP10 are recruited to the lung after Mycobacterium tuberculosis infection. J Exp Med 2004 200 : 1479 1489.
24. Shi CH, Wang XW, Zhang H, Zhang TF, Wang LM, Xu ZK. Immune responses and protective efficacy of the gene vaccine expressing Ag85B and ESAT6 fusion protein from Mycobacterium tuberculosis. DNA Cell Biol 2008 27 : 199 207.
25. Bai Y, Xue Y, Gao H et al. Expression and purification of Mycobacterium tuberculosis ESAT-6 and MPT64 fusion protein and its immunoprophylactic potential in mouse model. Protein Expr Purif 2008 59 : 189 196.
26. Fan XL, Yu TH, Gao Q, Yao W. Immunological properties of recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing fusion protein IL-2-ESAT-6. Acta Biochim Biophys Sin 2006 38 : 683 690.
27. Feng Y, Yang X, Liu Z et al. Continuous treatment with recombinant Mycobacterium tuberculosis CFP10-ESAT6 protein activated human monocyte while deactivated LPS-stimulated macrophage. Biochem Biophys Res Commun 2008 365 : 534 540.
28. Maue AC, Waters WR, Palmer MV et al. An ESAT-6:CFP10 DNA vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent M. bovis. Vaccine 2007 25 : 4735 4746.
29. Okkels LM, Müller EC, Schmid M et al. CFP10 discriminates between nonacetylated and acetylated ESAT-6 of Mycobacterium tuberculosis by differential interaction. Proteomics 2004 4 : 2954 2960.
30. Shi CH, Zhang H, wang LM et al. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene. Tuberculosis (Edinb) 2009 89 : 54 61.
31. Nosareva O, Nesterov A, Boldyrev A et al. Construction of an encapsulated ESAT-6-based anti-TB DNA vaccine and evaluation of its immunogenic properties. Biol Chem 2008 389 : 579 583.
32. Xu J, Xu W, Chen X, Zhao D, Wang Y. Recombinant DNA vaccine of the early secreted antigen ESAT-6 by Mycobacterium tuberculosis and Flt3 ligand enhanced the cell-mediated immunity in mice. Vaccine 2008 26 : 4519 4525.
33. Yu JS, Peacock JW, Jacobs WR Jr. et al. Recombinant Mycobacterium bovis bacillus Calmette-Guérin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites. Clin Vaccine Immunol 2007 14 : 886 893.
34. Yue Q, Hu X, Yin W et al. Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice. J Virol Methods 2007 141 : 41 8.
35. Chade DC, Borra RC, Nascimento IP et al. Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J Exp Clin Cancer Res 2008 27 : 78.
36. Navalkar RG. Comparative analysis of the antigens of M. tuberculosis H37Rv with various mycobacterial antigens. Zentralbl Bakteriol 1977 237 : 330 336.
37. Post FA, Manca C, Neyrolles O, Ryffel B, Young DB, Kaplan G. Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits Mycobacterium smegmatis-induced cytokine production by human macrophages in vitro. Infect Immun 2001 69 : 1433 1439.
38. DasGupta SK, Jain S, Kaushal D, Tyagi AK. Expression systems for study of mycobacterial gene regulation and development of recombinant BCG vaccines. Biochem Biophys Res Commun 1998 246 : 797 804.
39. Yi Z, Fu Y, Yang C et al. Recombinant M. smegmatis vaccine targeted delivering IL-12/GLS into macrophages can induce specific cellular immunity against M. tuberculosis in BALB/c mice. Vaccine 2007 25 : 638 648.
40. Kuehnel MP, Goethe R, Habermann A et al. Characterization of the intracellular survival of Mycobacterium avium ssp. paratuberculosis: phagosomal pH and fusogenicity in J774 macrophages compared with other mycobacteria. Cell Microbiol 2001 3 : 551 566.
41. Luo Y, Chen X, Szilvasi A, O'Donnell MA. Co-expression of interleukin-2 and green fluorescent protein reporter in mycobacteria: in vivo application for monitoring antimycobacterial immunity. Mol Immunol 2000 37 : 527 536.
42. Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006 4 : 469 476.
43. Orme IM. Current progress in tuberculosis vaccine development. Vaccine 2005 23 : 2105 2108.
44. + T cells that are cytotoxic and display Th1-like cytokine secretion profile: heterogeneity in cytotoxic activity and cytokine secretion levels. Eur J Immunol 1993 23 : 2189 2195.
45. + cytotoxic T cell clones: a novel potentially immunoregulatory T-T cell interaction in man. J Exp Med 1990 171 : 2011 2024.
46. Bastian M, Braun T, Bruns H, Röllinghoff M, Stenger S. Mycobacterial lipopeptides elicit CD4+ CTLs in Mycobacterium tuberculosis-infected humans. J Immunol 2008 180 : 3436 3446.
47. + T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon and nitric oxide synthase 2. J Exp Med 2000 192 : 347 358.
48. Roupie V, Leroy B, Rosseels V et al. Immunogenicity and protective efficacy of DNA vaccines encoding MAP0586c and MAP4308c of Mycobacterium avium subsp. paratuberculosis secretome. Vaccine 2008 26 : 4783 4794.
49. Vipond J, Vipond R, Allen-Vercoe E et al. Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge. Vaccine 2006 24 : 6340 6350.
50. Nuermberger E. Using animal models to develop new treatments for tuberculosis. Semin Respir Crit Care Med 2008 29 : 542 551.
51. Wu B, Huang C, Garcia L et al. Unique Gene expression profiles in infants vaccinated with different strains of Mycobacterium bovis Bacille Calmette-Guérin. Infect Immun 2007 75 : 3658 3664.
52. Ritz N, Hanekom WA, Robins-Browne R, Britton WJ, Curtis N. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev 2008 32 : 821 841.
53. Hernández-Pando R, Orozcoe H, Sampieri A et al. Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 1996 89 : 26 33.